

The Clinical Characteristics of Normoalbuminuric Renal Insufficiency in Korean Type 2 Diabetic Patients: A Possible Early Stage Renal Complication

It has been recently reported that a considerable portion of diabetic patients with renal insufficiency show normoalbuminuria. As little is known about normoalbuminuric renal insufficiency in the Asian population, we examined its prevalence and clinical characteristics in Korean type 2 diabetic patients. We studied 562 patients with type 2 diabetes from Seoul National University Hospital. The estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease formula and the degree of albuminuria was evaluated by spot urine albumin-creatinine ratio. Of 562 patients, 151 (26.9%) patients had renal insufficiency (eGFR <60 mL/min/1.73m²). Among them, 44 (29.1%) patients had normoalbuminuria. After excluding the patients using renin-angiotensin system (RAS) inhibitors, the prevalence of normoalbuminuric renal insufficiency was 35.3% (18 of 51 patients). Compared with micro- and macroalbuminuric renal insufficiency, normoalbuminuric renal insufficiency was associated with the female predominance, shorter duration of diabetes, lower prevalence of diabetic retinopathy, and lower prevalence of using antihypertensive drugs except RAS inhibitors. The prevalence decreased progressively with an increase in the duration of diabetes and an increase in the severity of retinopathy. Normoalbuminuric renal insufficiency was prevalent in Korean type 2 diabetic patients. The association with a shorter duration of the diabetes and a lower prevalence of retinopathy suggests that it might be an early stage renal complication.

Key Words : Normoalbuminuria; Renal Insufficiency; Diabetes Mellitus; Type 2

Jee Hyun An, Young Min Cho,
Hyeong Gon Yu*, Hak Chul Jang,
Kyong Soo Park, Seong Yeon Kim,
and Hong Kye Lee

Departments of Internal Medicine and Ophthalmology*,
Seoul National University College of Medicine, Seoul,
Korea

Received : 15 July 2008
Accepted : 24 December 2008

Address for correspondence

Young Min Cho, M.D.
Department of Internal Medicine, Seoul National
University College of Medicine, 28 Yeongeon-dong,
Jongno-gu, Seoul 110-744, Korea
Tel : +82-2-2072-1965, Fax : +82-2-762-5286
E-mail : ymchomd@snu.ac.kr

*This study was supported by a grant from the Korea
Health 21 R & D Project, Ministry of Health & Welfare,
Republic of Korea (00-PJ3-PG6-GN07-001).

INTRODUCTION

There have been many efforts for the early detection and management of diabetic nephropathy, which is the leading cause of end-stage renal disease (ESRD) (1, 2). Microalbuminuria is the initial clinical evidence and an increased albumin excretion rate (AER) is one of the most conventional parameters for the progression of diabetic nephropathy (3, 4). Measuring AER as a marker of diabetic nephropathy is based on the natural history of nephropathy in type 1 diabetes (5-10). However, in type 2 diabetes, there are many other factors that can contribute to renal insufficiency without causing albuminuria, such as atherosclerosis in renal vasculature, cholesterol emboli, and interstitial fibrosis (11, 12).

It has been reported that a decline in the renal function of patients with diabetes is not always accompanied by an increased AER (13, 14). About 20-30% of type 2 diabetics with renal insufficiency showed normoalbuminuria (12-18). In the Third National Health and Nutrition Examination Survey, the prevalence of patients with type 2 diabetes and renal insufficiency in the absence of both albuminuria and

retinopathy was about 30% (12). Compared with the renal insufficiency with albuminuria, the patients with normoalbuminuric renal insufficiency were characterized by female predominance, older age, higher HDL cholesterol, lower prevalence of retinopathy, and possibly better prognosis (15-17). In addition, compared with diabetic patients with normoalbuminuria and normal renal function, patients with normoalbuminuric renal insufficiency had an increased risk of cardiovascular disease and metabolic syndrome (18-20). Therefore, normoalbuminuric renal insufficiency is a distinct entity in diabetic renal complications. However, the natural course and pathophysiologic mechanism of normoalbuminuric renal insufficiency are still elusive.

It has been shown that ESRD accounts for 10-30% of the deaths in Asian diabetic patients, which clearly contrasts with a <5-10% risk of renal death in Caucasian diabetic patients (21). Furthermore, a 4-yr follow up study showed that Asian diabetic patients are at high risk of progression to ESRD compared with Caucasian diabetic patients (22). These data suggest that Asian patients are more susceptible to diabetic renal disease compared with Caucasians. In this regard, the clin-

cal characteristics of normoalbuminuric renal insufficiency in Asian diabetic patients might be different from their Caucasian counterparts.

We therefore performed a study on the prevalence and clinical characteristics of Korean type 2 diabetic patients with normoalbuminuric renal insufficiency and examined its relations to renin-angiotensin system (RAS) inhibitors, diabetic retinopathy, and the duration of the diabetes.

MATERIALS AND METHODS

Study population

We studied 562 randomly selected patients from the Diabetes Clinic at Seoul National University Hospital from January to December, 2006, who were diagnosed with type 2 diabetes. Excluded from this study were those patients with anti-GAD antibodies; those who started insulin therapy within the first year after diagnosis; those with a urinary tract infection, hematuria, or other causes of renal insufficiency; those with cardiac or hepatic failure; and those with a severe intercurrent illness, including malignancy. The Institutional Review Board of the Clinical Research Institute in Seoul National University Hospital approved the study protocol.

Estimation of glomerular filtration rate (GFR)

We calculated the GFR with the Modification of Diet in Renal Disease (MDRD) formula (23) and defined renal insufficiency as an estimated GFR (eGFR) of less than 60 mL/min per 1.73 m² body surface area (BSA), which corresponded to the National Kidney Foundation Kidney Dialysis Outcomes Quality Initiative guideline (24).

Quantification of albuminuria

We measured the degree of albuminuria with spot tests of the urine albumin-creatinine ratio (ACR). Urinary albumin levels were measured by turbidimetry assay (A&T 502X, A&T, Tokyo, Japan) and urine creatinine levels were measured by the Jaffe method (Hitachi 7170, Hitachi, Tokyo, Japan).

We used sex-specific ACR cut points to define micro- and macroalbuminuria (25, 26). Microalbuminuria was defined as an ACR from 17 to 250 µg/mg for males and from 25 to 355 µg/mg for females. Macroalbuminuria was defined as an ACR over 250 µg/mg and over 355 µg/mg for males and females, respectively. Albuminuria denotes the presence of micro- or macroalbuminuria.

Assessment of covariates

Questionnaires and review of the patients' medical records

were used to evaluate the history of stroke, coronary artery disease, and peripheral vascular disease. Hypertension was defined as a systolic blood pressure over 140 mmHg or a diastolic blood pressure over 90 mmHg, or the fact that the patient was taking antihypertensive medications. Drug histories in relation to anti-hypertensive agents and lipid lowering agents were also evaluated. Fasting plasma glucose, HbA1c, serum creatinine, blood urea nitrogen (BUN), serum albumin, total cholesterol, triglyceride, LDL-cholesterol, and HDL-cholesterol concentrations were measured. Diabetic retinopathy was evaluated by direct fundus examination and was graded according to the modified Airlie House Classification (27).

Statistical analysis

All continuous variables with normal distributions were expressed as means ± SD, while variables with skewed distributions were expressed as medians with a range. Variables not normally distributed were logarithmically transformed before statistical analysis. The results of categorical data are expressed as percentages. Student's t-test and ANOVA were used to compare the continuous variables between groups and the chi-square test was used for categorical variables. The *p* value for a trend was evaluated by the Mantel-Haenszel chi-square test. A level of *p*<0.05 was considered statistically significant. All data were analyzed using SPSS for Windows (SPSS Inc., Chicago, IL, U.S.A.).

RESULTS

A total of 562 patients were enrolled in this study. Their mean age was 59±10 yr; the mean duration of diabetes was 8.0±7.4 yr; and their mean eGFR was 71.3±11.5 mL/min per 1.73m². There was a significant inverse correlation between ACR and eGFR (*r*=-0.651, *p*<0.001) (Fig. 1). In the patients




Fig. 1. Inverse linear relationship between albumin-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR).

with eGFR <60 mL/min/1.73m², the coefficient of correlation between ACR and eGFR slightly decreased ($r=-0.552$, $p<0.001$).

Among 562 patients, 151 (26.9%) had renal insufficiency, defined as an eGFR <60 mL/min per 1.73 m². Among these, the prevalence of normo-, micro-, and macroalbuminuric patients was 29.1% (n=44), 33.1% (n=50), and 37.8% (n=57), respectively. After excluding the patients using RAS inhibitors (angiotensin converting enzyme inhibitors or angiotensin II receptor blockers), the number of patients with

Table 1. The prevalence of type 2 diabetic patients classified according to estimated glomerular filtration rate (eGFR) and albumin excretion rate (AER) status

		Normo-albuminuria	Micro-albuminuria	Macro-albuminuria
All (n=562)	eGFR ≥60	305 (74.2)	96 (23.4)	10 (2.4)
	eGFR <60	44 (29.1)	50 (33.1)	57 (37.8)
Without	eGFR ≥60	67 (81.7)	15 (18.3)	0 (0.0)
RAS inhibitors (n=133)	eGFR < 60	18 (35.3)	21 (41.2)	12 (23.5)

Data are expressed as n (%).

renal insufficiency was 51 and the prevalence of normo-, micro-, and macroalbuminuric renal insufficiency was 35.3% (n=18), 41.2% (n=21), and 23.5% (n=12), respectively (Table 1).

The characteristics of the 151 patients with an eGFR <60 mL/min per 1.73 m² stratified according to their ACR, as shown in Table 2. Compared with microalbuminuric renal insufficiency, normoalbuminuric renal insufficiency was associated with female predominance, shorter duration of diabetes, lower BUN and creatinine, higher eGFR, and lower HbA1c. In addition, patients with normoalbuminuric renal insufficiency had a lower prevalence of hypertension and retinopathy, and a lower prevalence of using anti-hypertensive drugs except RAS inhibitors. Among them, female predominance, lower HbA1c, shorter duration of diabetes, lower prevalence of hypertension and retinopathy, and a lower prevalence of using antihypertensive drugs other than RAS inhibitors were still significant, even after adjusting for their eGFR. When the patients using RAS inhibitors were excluded, we obtained similar results (data not shown). Next, we compared the characteristics of the patients with normoalbuminuric renal insufficiency with those who had macroalbuminuric renal insufficiency. The results showed very similar trends to those of

Table 2. Clinical and laboratory characteristics of type 2 diabetic patients with renal insufficiency according to albumin excretion ratio (AER) status

	Normo-albuminuria	Micro-albuminuria	Macro-albuminuria	<i>p</i> value ¹	<i>p</i> value ²
Number	44 (29)	50 (33)	57 (38)	-	-
Age (yr)	59±11	57±8	61±9	0.94	0.76
Sex (% female)	77	66*†	42*†	<0.01	<0.01
Duration of diabetes (yr)	5.5±2.3	9.3±3.6*†	19.5±5.8*†	<0.01	<0.01
Body mass index (kg/m ²)	25.2±2.6	23.9±3.0	24.1±2.8	0.14	0.43
Systolic blood pressure (mmHg)	127±16	130±16	135±15	0.56	0.63
Diastolic blood pressure (mmHg)	72±11	75±11	76±10	0.37	0.47
BUN (mM/L)	6.1±1.4	8.6±1.4*	17.5±8.6*	0.03	0.01
Creatinine (μM/L)	110±30	130±20*	270±70*	0.04	<0.01
Hemoglobin (g/dL)	14.0±1.4	15.6±1.8	12.0±2.0	0.46	0.62
HbA1c (%)	7.0±1.1	7.9±1.2*†	7.2±1.2	<0.01	0.85
Cholesterol (mM/L)	4.42±1.03	4.37±0.91	4.60±0.98	0.76	0.74
Triglycerides (mM/L)	1.67±0.94	1.76±0.90	1.75±1.01	0.65	0.69
HDL-Cholesterol (mM/L)	1.19±0.31	1.16±0.28	1.14±0.26	0.53	0.75
LDL-Cholesterol (mM/L)	2.46±0.83	2.38±0.85	2.64±0.67	0.67	0.71
Urine ACR (μg/mg)	8.5±4.8	116.5±84.3*	2916.9±534.9*	<0.01	<0.01
eGFR (mL/min/1.73 m ²)	48.3±5.2	42.2±8.3*	21.4±11.6*	0.03	<0.01
Hypertension, n (%)	16 (36)	26 (52)*†	51 (89)*†	<0.01	<0.01
Smoking, n (%)	8 (18)	9 (18)	11 (19)	0.78	0.83
Retinopathy, n (%)	7 (15)	28 (56)*†	46 (81)*†	<0.01	<0.01
Coronary artery disease, n (%)	8 (18)	10 (20)	18 (32)	0.78	0.43
Cerebrovascular disease, n (%)	3 (7)	6 (12)	7 (12)	0.73	0.82
Peripheral vascular disease, n (%)	1 (2)	2 (4)	3 (5)	0.50	0.46
RAS inhibitors, n (%)	26 (47)	29 (55)	45 (68)	0.65	0.37
Other antihypertensive drugs, n (%)	5 (11)	20 (40)*†	47 (82)*†	<0.01	<0.01
Statins, n (%)	17 (39)	29 (58)	38 (67)	0.37	0.18

Data are means±SD or n (%) unless otherwise indicated. *means $p<0.05$ vs. the normoalbuminuric group; †means $p<0.05$ vs. the normoalbuminuric group after exclusion of the patients using renin-angiotensin system inhibitors and after adjustment for GFR. *p* value¹ means the significance of the difference between the normo- and micro-albuminuric groups. *p* value² means the significance for the trend that follows the normo-, micro- and macroalbuminuric groups.

Table 3. Clinical and laboratory characteristics of type 2 diabetic patients with normoalbuminuria according to eGFR

	eGFR ≥ 60	eGFR < 60	p value
Number	305	44	-
Age (yr)	51±7	59±11	0.04*
Sex (% Female)	47	76	<0.01*
Duration of diabetes (yr)	5.7±2.8	5.5±2.3	0.65
Body mass index (kg/m ²)	24.1±3.1	25.2±2.6	0.14
Systolic blood pressure (mmHg)	119±18	127±16	0.25
Diastolic blood pressure (mmHg)	75±12	72±11	0.57
BUN (mM/L)	5.4±1.4	6.1±1.4	<0.01
Creatinine (μM/L)	80±20	110±30	<0.01
Hemoglobin (g/dL)	14.1±1.5	14.0±1.4	0.57
HbA1c (%)	7.2±1.4	7.0±1.1	0.65
Cholesterol (mM/L)	4.78±1.06	4.42±1.03	0.11
Triglycerides (mM/L)	1.71±1.09	1.67±0.94	0.48*
HDL-Cholesterol (mM/L)	1.27±0.28	1.19±0.31	0.09*
LDL-Cholesterol (mM/L)	2.72±0.96	2.48±0.83	0.25
Urine ACR (μg/mg)	8.4±5.1	8.5±4.8	0.79
eGFR (mL/min/1.73 m ²)	75.3±9.8	48.3±5.2	<0.01
Hypertension, n (%)	101 (33)	16 (36)	0.21
Smoking, n (%)	40 (13)	8 (18)	0.14
Retinopathy, n (%)	34 (11)	7 (15)	0.23
Coronary artery disease, n (%)	27 (9)	8 (18)	0.02*
Cerebrovascular disease, n (%)	6 (2)	3 (7)	0.12
Peripheral vascular disease, n (%)	3 (1)	1 (2)	0.87
RAS inhibitors, n (%)	55 (18)	26 (47)	<0.01
Other antihypertensive drugs, n (%)	37 (12)	11 (25)	0.15
Statins, n (%)	40 (13)	17 (39)	<0.01

Data are means±SD or n (%) unless otherwise indicated. *means p<0.05 after exclusion of the patients using renin-angiotensin system inhibitors and statins.




Fig. 2. The relationship between the degree of urinary albumin excretion and the duration of diabetes in type 2 diabetic patients with renal insufficiency. p for trend <0.001 by Mantel-Haenszel χ^2 test.

the comparison between normo- and microalbuminuric renal insufficiency, except for HbA1c, which was comparable between

the two groups. Finally, we found that female predominance, shorter duration of diabetes, lower prevalence of hypertension and retinopathy, and a lower prevalence of using antihypertensive drugs except RAS inhibitors showed significant trends across the degree of albuminuria.

Table 3 compares the clinical characteristics of 349 patients with normoalbuminuria according to their eGFR. The patients with normoalbuminuric renal insufficiency (n=44, 12.6%) were older, more likely to be female, had a higher prevalence of using RAS inhibitors and statins, and a higher prevalence of coronary artery disease. The patients with normoalbuminuric renal insufficiency, who were not taking RAS inhibitors or statins, showed similar results but they additionally showed higher triglyceride levels (1.83 [0.59-8.20] vs. 1.69 [0.65-6.53] mM/L, $p=0.03$; expressed as a median [range]) and lower HDL-cholesterol levels (1.01 ± 0.23 vs. 1.24 ± 0.28 mM/L, $p=0.02$) compared to their counterparts with normal renal function.

We evaluated the trend of changes in the prevalence of normo-, micro-, and macroalbuminuric renal insufficiency along with the duration of the diabetes. The prevalence of normoalbuminuria decreased progressively, whereas the prevalence of macroalbuminuria increased with an increase in the duration of diabetes (Mantel-Haenszel χ^2 test, p for trend <0.001) (Fig. 2).

Table 4. The prevalence of retinopathy in type 2 diabetic patients with renal insufficiency

	Normo-albuminuria	Micro-albuminuria	Macro-albuminuria
No retinopathy	37 (84.1)	22 (44.0)	11 (19.3)
Non-proliferative, mild	5 (11.3)	10 (20.0)	7 (12.3)
Non-proliferative, moderate	1 (2.3)	7 (14.0)	9 (15.8)
Non-proliferative, severe	1 (2.3)	5 (10.0)	11 (19.3)
Proliferative	0 (0)	6 (12.0)	19 (33.3)

Data are expressed as n (%). *p* for trend <0.001 by Mantel-Haenszel chi-square test.

Table 4 shows the prevalence of the respective grade of retinopathy according to the AER status of the patients with renal insufficiency. The retinopathy and albuminuria were both absent in 37 of the 151 (24.5%) patients. In the normoalbuminuric renal insufficiency group, most of the patients (37 of 44 patients, 84.1%) had no retinopathy. The prevalence and severity of retinopathy were markedly and progressively increased in the micro- and macroalbuminuria groups (Mantel-Haenszel chi-square test, *p* for trend <0.001).

DISCUSSION

Among the Korean patients with type 2 diabetes and renal insufficiency, the prevalence of normoalbuminuria was 29.1% (35.3% in those not using RAS inhibitors). Even after adjusting for their eGFR, normoalbuminuric renal insufficiency was associated with female predominance, lower HbA1c, shorter duration of diabetes, lower prevalence of hypertension and retinopathy, and a lower prevalence of using antihypertensive drugs except RAS inhibitors compared with microalbuminuric renal insufficiency. These results are largely similar to those from Caucasian studies (15-17). The characteristics of a shorter duration of the diabetes and a lower prevalence of retinopathy found in this study suggest that normoalbuminuric renal insufficiency might be an earlier stage of renal insufficiency compared with microalbuminuric renal insufficiency. This is further supported by the results that the prevalence of normoalbuminuric renal insufficiency decreased with an increase in the duration of the diabetes and with the advanced stage of retinopathy. Thus, it might be speculated that some type 2 diabetic patients might face renal insufficiency without albuminuria and may then progress to microalbuminuric and macroalbuminuric renal insufficiency as the duration of type 2 diabetes increases. However, there are reports showing that normoalbuminuric renal insufficiency was not associated with a lower prevalence of retinopathy (15, 16). Furthermore, Rigalleau et al. (17) reported that diabetic patients with normoalbuminuric renal insufficiency showed stable AER over 38 months and had a low risk for the progression to ESRD or death. Therefore, to support our hypothesis that normoal-

buminuric renal insufficiency might be an earlier stage of diabetic renal complication, we need a prospective study including looking into the change of renal pathology.

In the next step, we examined whether there was any difference in the clinical characteristics of normoalbuminuric patients according to their eGFR. Compared with the patients with normoalbuminuria in the absence of renal insufficiency, those with normoalbuminuric renal insufficiency were older, more likely to be female, had a higher prevalence of using RAS inhibitors and statins, and a higher prevalence of coronary artery disease. The higher prevalence of coronary artery disease suggests that other atherosclerotic diseases involving the renal vasculature might be responsible for the decreased renal function in the absence of albuminuria. In this regard, a recent report (18) also showed that normoalbuminuric renal insufficiency was associated with metabolic syndrome. However, MacIsaac et al. (16) found that patients with type 2 diabetes and reduced GFR had similar degrees of intrarenal vascular disease, assessed by the intrarenal arterial resistance index. Therefore, at this time, the mechanism of normoalbuminuric renal insufficiency still remains elusive. Interestingly, genetic susceptibility might play a role in the development of normoalbuminuric renal insufficiency. It has been reported that polymorphisms of the protein kinase C-β gene (PRKCB1) were associated with diabetic nephropathy that did not lead to albuminuria in Japanese patients (28).

A female predilection for normoalbuminuric renal insufficiency has been noted in many other previous studies (14, 15, 17, 18), but the reason for this association is unknown. In this study, the patients with normoalbuminuric renal insufficiency were more likely to be females over 50 (odds ratio [OR] and 95% confidence interval [CI] was 3.08 [1.15-4.13], *p*=0.017), while we could not find this age effect in male subjects (OR and 95% CI was 1.38 [0.48-3.26], *p*=0.646) (data not shown in the Results). Therefore, the pathogenesis of normoalbuminuric renal insufficiency might be affected by the hormonal change that occurs around menopause.

There were several limitations in this study. First, owing to the cross-sectional design it was difficult to clarify the causal relationship between the risk factors and the natural course of the normoalbuminuric renal insufficiency. Second, the eGFR might not reflect the actual GFR of our study population, since the MDRD study included very few Asians (29). Third, the assessment of AER with a single specimen might not exactly estimate the number of normoalbuminuric renal insufficiency. Finally, the number of the patients with renal insufficiency not taking RAS inhibitors was somewhat small. Therefore, a further study including sufficient number of patients in this category is necessary.

In conclusion, normoalbuminuric renal insufficiency was prevalent in type 2 diabetic Korean patients and the clinical characteristics were largely similar to those seen in previous studies. The association with a shorter duration of the diabetes and a lower prevalence of retinopathy suggests that normoal-

buminuric renal insufficiency might be an early stage renal complication in Korean type 2 diabetic patients.

REFERENCES

- Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, Grimm R, Liu J, Louis T, Manning W, Matas A, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li S, Roberts T, Snyder J, Solid C, Wang C, Weinhandl E, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebbin J, Frazier E, Johnson R, Sheets D, Forrest B, Berrini D, Constantini E, Everson S, Frederick P, Eggers P, Agodoa L. *Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States*. Am J Kidney Dis 2005; 45 (1 Suppl 1): A5-7, S1-280.
- Ritz E, Rychlik I, Locatelli F, Halimi S. *End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions*. Am J Kidney Dis 1999; 34: 795-808.
- Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. *Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74*. Diabetes 2006; 55: 1832-9.
- Mogensen CE. *Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas*. Diabetologia 1999; 42: 263-85.
- Mogensen CE, Christensen CK. *Predicting diabetic nephropathy in insulin-dependent patients*. N Engl J Med 1984; 311: 89-93.
- Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR. *Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion*. Acta Endocrinol (Copenh) 1982; 100: 550-5.
- Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH. *Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study*. BMJ 2004; 328: 1105.
- Forsblom CM, Groop PH, Ekstrand A, Groop LC. *Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration*. BMJ 1992; 305: 1051-3.
- Rossing P, Hougaard P, Parving HH. *Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study*. Kidney Int 2005; 68: 1446-50.
- Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N. *Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study*. Diabetologia 2004; 47: 1020-8.
- Rychlik I, Jancova E, Tesar V, Kolsky A, Lacha J, Stejskal J, Stejskalova A, Dusek J, Herout V. *The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000*. Nephrol Dial Transplant 2004; 19: 3040-9.
- Kramer HJ, Nguyen QD, Curhan G, Hsu CY. *Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus*. JAMA 2003; 289: 3273-7.
- Lane PH, Steffes MW, Mauer SM. *Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion*. Diabetes 1992; 41: 581-6.
- Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G. *Progressive decline in renal function in diabetic patients with and without albuminuria*. Diabetes 1994; 43: 649-55.
- MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. *Nonalbuminuric renal insufficiency in type 2 diabetes*. Diabetes Care 2004; 27: 195-200.
- MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, Matthews PG, Thomas MC, Power DA, Jerums G. *Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?* Diabetes Care 2006; 29: 1560-6.
- Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, Combe C, Gin H. *Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group*. Diabetes Care 2007; 30: 2034-9.
- Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. *Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria*. Diabetes Care 2007; 30: 1998-2000.
- Knobler H, Zornitzki T, Vered S, Oettinger M, Levy R, Caspi A, Faraggi D, Livschitz S. *Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria*. J Am Coll Cardiol 2004; 44: 2142-8.
- Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V. *All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study*. Diabet Med 2007; 24: 10-7.
- Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. *Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes*. Diabetologia 2001; 44 (Suppl 2): S14-21.
- Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. *Ethnic disparities in diabetic complications in an insured population*. JAMA 2002; 287: 2519-27.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. *A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation*. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
- KDOQI. *KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease*. Am J Kidney Dis 2007; 49 (2 Suppl 2): S12-154.
- Mattix HJ, Hsu CY, Shaykevich S, Curhan G. *Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race*. J Am Soc Nephrol 2002; 13: 1034-9.
- Warram JH, Gearin G, Laffel L, Krolewski AS. *Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio*. J Am Soc Nephrol 1996; 7: 930-7.
- Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci 1981; 21: 1-226.
- Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. *Polymorphisms of the protein kinase C-beta gene (PRKCB1)*

accelerate kidney disease in type 2 diabetes without overt proteinuria.
Diabetes Care 2006; 29: 864-8.

29. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. *Performance*

of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease.
J Am Soc Nephrol 2005; 16: 459-66.